TABLE 1

Clinical data, evolution, and treatment of the case after first admission at intensive care unita

Day after admission or readmission (treatment)Clinical event(s)SampleTime to positivityIsolate
Initial admission
    1Admitted at ICU; feverBS1
HSB12.6 daysYeast (Y1)
    3No clinical signs of illness; discharged
Readmission: 4 days after initial admission
    1 (ceftazidime and amikacin)Fever, vomiting, and dehydration; WBCs, 200/mm3BS218 hP. aeruginosa
HSB218 hP. aeruginosa
    4Fever; WBCs, 80/mm3; CRP, 233 mg/literBS312 hE. coli
HSB314 hYeast (Y2)
    6 (meropenem and amikacin [for extended-spectrum-beta-lactamase-producing E. coli])Mouth bullous lesions and acute tubular necrosis
    8 (meropenem and amikacin [for extended-spectrum-beta-lactamase-producing E. coli])BS43.5 daysYeast (Y3)
CVCYeast (<100 CFU/ml)
    10 (liposomal amphotericin B [for 14 days])Fever; WBCs, 130/mm3; CRP, 178 mg/literBS5
HSB43.7 daysYeast (Y4)
    15BS6
HSB5
PVC
    24No clinical signs of illness
  • a WBCs, white blood cells; CRP, C-reactive protein; BS, blood sample; HBS, catheter hub blood sample; PVC, peripheral venous catheter.